Curefab Technologies GmbH
Curefab provides innovative technologies to make the interpretation of diagnostic image data more objective, more economical and more reliable..
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
N/A | Seed | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (3 %) | 10 % | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 2 % | 3 % | 10 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Curefab Technologies GmbH is a medical technology firm based in Munich, Germany, specializing in the development of technologies to enhance diagnostic imaging data. Founded in 2009 as a venture-backed entity, the company initially focused on a certified freehand-tracked 6 DOF ultrasound analysis system. The first prototype was developed for the German Heart Centre Munich in 2008 and was further enhanced with support from the University Hospital Klinikum rechts der Isar in Munich. Over the years, Curefab has grown independently and is now led by managing director Sebastian Wittmeier, who has a background in computer science and physics.
The company operates in the medical technology market, serving clients in industry and research. Its business centers on providing advanced tools for early diagnosis and prevention of conditions like stroke, vascular diseases, and for monitoring cancer therapies. Curefab's primary product, Curefab CS, is an add-on for conventional ultrasound machines that upgrades them with 3D capabilities. This system uses recorded 2D ultrasound data to automatically segment blood vessels and other structures, providing physicians with more detailed and comparable diagnostic parameters over time. The technology aims to offer a cost-effective and non-invasive alternative to more expensive or invasive methods like MRI and CT scans.
Curefab's core competencies lie in the research and development of medical devices, encompassing everything from software to hardware. Their expertise includes algorithms, GPU acceleration, electronics, and 3D printing. The company also offers custom-embedded systems, creating AI and edge computing solutions, and specializes in GPU-accelerated algorithms for image recognition and 3D image reconstruction. The company has received funding from investors such as High-Tech Gründerfonds and Bayern Kapital. It holds certifications for ISO 9001 and ISO 13485.
Keywords: medical imaging, diagnostic technology, ultrasound analysis, 3D imaging, stroke prevention, vascular disease diagnosis, oncology monitoring, computed sonography, medical device R&D, GPU acceleration, embedded systems, AI in healthcare, edge computing, image recognition, 3D image reconstruction, medical algorithms, medtech, healthtech, diagnostic equipment, ISO 13485